This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Social Bookmarking   What's this?

The COMS Outcomes for Medium-Sized Choroidal Melanoma

Arch Ophthalmol. 2001;119:1067-1068.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

CHOROIDAL MELANOMA is the most common primary ocular malignancy, with some 1500 new cases reported yearly in the United States. These tumors are both sight- and life-threatening, with approximately a 10% to 30% five-year mortality rate owing to systemic metastasis, depending on tumor size. Despite the major morbidity and mortality from these tumors, the condition occurs infrequently enough in any single ophthalmic practice of considerable size that clinical expertise in the condition had been difficult to accumulate in years past. Even the accurate diagnosis of choroidal melanoma had been sufficiently difficult to make, and an unfortunate fraction of eyes enucleated were found to have some other condition.

The most appropriate treatment for choroidal melanoma was also uncertain. Enucleation was the standard treatment of the time when Zimmerman and McLean et al^1-2 raised a question in the late 1970s as to whether enucleation might cause tumor dissemination and thereby increase the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, II: Characteristics of Patients Enrolled and Not Enrolled: COMS Report No. 17
The Collaborative Ocular Melanoma Study Group
Arch Ophthalmol. 2001;119(7):951-965.
ABSTRACT | FULL TEXT  

The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, III: Initial Mortality Findings: COMS Report No. 18
The Collaborative Ocular Melanoma Study Group
Arch Ophthalmol. 2001;119(7):969-982.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

18 Years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma
van Ginderdeuren et al.
Br J Ophthalmol 2005;89:1306-1310.
ABSTRACT | FULL TEXT